Search clinical trials for: Epidermal

Total 795 results

Sun Yat-sen University

Completed

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment (EGFR-TKIs)

Non-small Cell Lung Cancer

China
AbbVie

Completed

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Advanced Solid Tumors Cancer

United States, Australia, Israel
ISU Abxis Co., Ltd.

Active, not recruiting

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Solid Tumor

Korea, Republic of
Hoffmann-La Roche

Completed

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)

Breast Neoplasms

Hungary, Italy, United Kingdom, Canada, Czechia, Bulgaria, Croatia, Dominican Republic, France, Germany, Greece, Guatemala, Hong Kong, Indonesia, Ireland, Korea, Republic of, Netherlands, Panama, Peru, Poland, Portugal, Slovakia, Spain and more
University of Minnesota

Withdrawn

Allogeneic Skin Grafting

GVHD

United States
AbbVie

Terminated

UNITE Study: Understanding New Interventions With GBM ThErapy

Glioblastoma Multiforme

United States, Australia, Germany, Netherlands, United Kingdom
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

Healthy Volunteers

China
Vanderbilt University Medical Center

Completed

Pain Outcomes Following Intralesional Corticosteroid Injections

Plaque Psoriasis | Morphea | Alopecia Areata | Acne | Lichen Planus | Keloid | Prurigo Nodularis | Hypertrophic Scar | Frontal Fibrosing Alopecia | Keratoacanthoma | Granuloma Annulare | Nummular Eczema | Lichen Simplex Chronicus | Lichen Plano-Pilaris | Epidermal Inclusion Cyst

United States
European Organisation for Research and Treatment...

Active, not recruiting

Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study (GEM)

EGFR Mutation Positive Non Small Cell Lung Cancer

United Kingdom
PepsiCo Global R&D

Completed

Sweat Patch Validation

Sweat Analysis

United States
National Cancer Institute, Egypt

Completed

The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

Prostate Cancer Metastatic

Egypt
Novartis Pharmaceuticals

Completed

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (BOLERO-6)

Breast Cancer

Belgium, Hungary, Spain, Argentina, Russian Federation, Sweden, Lebanon, Australia, Denmark, Ireland, United Kingdom, Thailand, Turkey, Peru, Brazil, Malaysia, India, United States
Novartis Pharmaceuticals

Completed

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Breast Neoplasms

United States, France, Spain, United Kingdom, Croatia, Turkey, Netherlands, Argentina, Australia, Canada, Czechia, Germany, Italy, Poland, Russian Federation, Brazil, Bulgaria, Chile, Denmark, Hungary, Ireland, Peru, South Africa, Col... and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2)

Metastatic Breast Cancer

United States, Korea, Republic of, United Kingdom, Germany, Spain, Taiwan, Australia, Canada, Italy
Save the Children
University of British Columbia; Bill and Melinda Gates Foundation; Aga Khan University and other collaborators

Completed

Evaluation of Technologies for Neonates in Africa (ETNA)

Neonatal Physiology

Kenya
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
Asan Medical Center

Completed

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Advanced Colorectal Cancer

Korea, Republic of
Hoffmann-La Roche

Terminated

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) (TRAXHER2)

Breast Cancer | Gastric Cancer

Italy, Argentina, Canada, France, Greece, Portugal, Slovakia, Brazil, Russian Federation, Spain, Germany, Serbia
Tesaro, Inc.

Completed

Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer

Neoplasms, Breast

United States
UNC Lineberger Comprehensive Cancer Center
Astellas Pharma Global Development, Inc.

Completed

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Non Small Cell Lung Cancer

United States
Hallym University Kangnam Sacred Heart Hospital

Completed

Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines

Hyperpigmentation | Epidermal Growth Factor | Post Inflammatory Hyperpigmentation | Nd-yttrium Aluminum Garnet Laser

Korea, Republic of
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB)

Gastric Cancer

Austria, Belgium, Brazil, Canada, China, Croatia, Finland, Hungary, Italy, Korea, Republic of, Mexico, Poland, Spain, Turkey, United States, Kazakhstan, Peru, Russian Federation, Switzerland, Taiwan, Thailand, Germany, Japan, Malaysia, ... and more
M.D. Anderson Cancer Center
Procter and Gamble

Completed

A Study of Actonel for the Prevention of Bone Loss

Lymphoma | Leukemia

United States
Hellenic Cooperative Oncology Group

Completed

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Gene Mutation
Takeda

Withdrawn

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Non-Small Cell Lung Cancer (NSCLC)
IRCCS San Raffaele
Menarini International Operations Luxembourg SA

Completed

Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

HCM - Hypertrophic Non-Obstructive Cardiomyopathy

Italy
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Spectrum Pharmaceuticals, Inc

Completed

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

EGFR Inhibitor-associated Rash

United States, Canada
Hoffmann-La Roche

Completed

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SCHEARLY)

Breast Cancer

Italy
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN)

Breast Cancer

United States, United Kingdom, France, Italy, Spain, Turkey, Brazil, India
Cynosure, Inc.

Completed

Evaluation of the 755nm Alexandrite Laser for Skin Toning and Epidermal Pigmented Lesions in Asian Skin Types

Epidermal Pigmented Lesions | Skin Toning

United States
Cynosure, Inc.

Completed

Evaluation of the 755nm Alexandrite for the Treatment of Epidermal and Dermal Pigmented Lesions

Dermal and Epidermal Pigmented Lesions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE)

Breast Neoplasms

Italy, Netherlands, Belgium, United Kingdom, Argentina, Austria, Brazil, China, Ecuador, Estonia, Finland, France, Germany, Greece, Mexico, Peru, Poland, Portugal, Slovenia, Spain, United Arab Emirates, Canada, Hungary, Israel, Sweden, Tu... and more
Hoffmann-La Roche

Completed

A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

Breast Cancer

France
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Bayer

Terminated

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Breast Neoplasms

Spain, Canada, United States, Finland, Austria, Singapore, Czechia, Israel, Korea, Republic of, Netherlands, Taiwan, United Kingdom, Poland, Germany, Hong Kong, Denmark, Switzerland, Ireland, France, Norway
University College, London

Completed

Epidermal Grafting in Wound Healing (EPIGRAAFT)

Wounds and Injuries | Ulcer | Skin Ulcer

United Kingdom
Clovis Oncology, Inc.

Terminated

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Locally Advanced or Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Poland
University of California, San Diego

Unknown

Epidermal Adhesive Sensors to Enhance Continuous Glucose Measurement in Patients With Diabetes: The EASE Study

Diabetes Mellitus

United States
First Affiliated Hospital of Harbin Medical University

Unknown

Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

Coronary Artery Disease

China
Cyprus University of Technology

Unknown

Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. (EGFR)

Breast Cancer | Head and Neck Cancer | Lung Cancer | Colon Cancer | Pancreas Cancer | Consent Form

Cyprus
Virginia Commonwealth University
Eli Lilly and Company; Bayer

Terminated

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
AstraZeneca

Completed

An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer). (ORTUS)

Non-Small Cell Lung Cancer

Russian Federation
AstraZeneca

Completed

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). (CONCORDANCE)

NSCLC (Non-small Cell Lung Cancer)

India

Search clinical trials for: Epidermal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations